Patent · US Active

Compounds

US11453644B1 · kind B1 · utility

0Cited by

3References

11Claims

0Family size

Assignee

ASTRAZENECA AB · SE

Inventors

Frank Narjes · Ariccia, IT
Roine Ingemar Olsson · Mölndal, SE
Stefan Von Berg · Mölndal, SE
Sarah Lever · Mölndal, SE

Key dates

Filing date	Mar 26, 2021
Grant date	Sep 27, 2022
Priority date	—
Expiry date	Mar 26, 2041

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D407/06
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present specification provides a compound of formula (I): or a pharmaceutically acceptable salt thereof; a process for preparing such a compound; and to the use of such a compound in the treatment of an RORγ and/or RORγt mediated disease state.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.